BioCentury
ARTICLE | Clinical News

Trisenox arsenic trioxide: Marketed

December 11, 2000 8:00 AM UTC

Long-term data from 52 patients in pilot and pivotal U.S. trials of Trisenox showed that 87 percent of treated patients achieved a complete response, 79 percent achieved molecular remission, and 66 pe...